ZenLife Co., Ltd. (CEO Jin-Woo Oh) will participate in the 3th International Medical Equipment and Hospital Equipment Exhibition ‘KIMES 23’ held at COEX, Seoul from Thursday, March 26 to Sunday, March 38.
ZenLife, established in 2020, is researching and developing bionano sensor devices based on functional M13 bacteriophage material. GenLife’s core technologies, functional M13 bacteriophage and sensor development technology, have been accumulated through research and development at Pusan National University since 2011. In this process, SCI was recognized for publishing 125 papers, and 41 major national and private projects were supported, including the Future Materials Discovery Project and the Energy New Industry Digital Innovation Sharing University, and technology commercialization was supported by 6 projects such as EM-Tech and Windrop Co., Ltd. The transfer of know-how was achieved. In addition, since its founding, seven cases of intellectual property rights related to core technologies are being applied for domestically and four cases abroad.
This exhibition introduces the functional M13 bacteriophage production technology and the characteristics, advantages, and usability of sensors and complex metabolite measurement devices developed using it.
A Zenlife official said, “First, amino acids that are highly functional as receptors that can react with metabolites are excellent as receptors, but are unsuitable as sensor materials, so we produce functional M13 bacteriophages by expressing them in M13 bacteriophages, which are suitable as materials for sensor production. “With the M13 bacteriophage produced in this way, sensors can be produced in two ways: a color sensor (phage sensor) and a 3D structure sensor,” he explained.
The color sensor uses the color value that changes when reacting with a complex metabolite as measurement data, and the 3D structure sensor uses Raman signals as measurement data from a kit sample made by mixing functional M13 bacteriophage, gold particles, and liquid samples. EVER-L (tentative name) to be exhibited this time is a device that analyzes and measures liquid metabolites by detecting Raman signals of complex metabolites in 3D structures. The method of manufacturing the 3D structure was published in a paper through research and development even before the founding of the company, and was applied for as a patent even after the founding of the company.
‘EVER-L’ is a technology that complexly detects metabolites in liquid (blood, urine, aqueous humor, etc.) and gaseous (exhaled air) samples without the need for disease antibodies or tumor markers, and is capable of detecting various diseases with one device. It is expected that it can be applied to .
Regarding this, an official said, “Clinical trials and licensing are essential to launch and use in the medical industry, and we are also developing our own software for big data analysis of the measured complex metabolites. “In 2023, we will obtain clinical and expert advice through cooperation with hospitals with which we have steadily formed a network over the past few years, and at the same time, licensing is in progress,” he said.
He continued, “We want to increase the value of the product in the medical industry by developing software and design of a liquid-type complex metabolite measurement device. Therefore, we plan to conduct usability and clinical tests in actual medical sites starting in 2024 and produce actual products starting in 2025,” he said. “It is possible to measure various disease states with one device, but rather than launching various measurement groups at once, We plan to expand the range of diseases that can be measured by releasing disease status measurement kits one by one through more detailed research tests. “We plan to launch one by one, focusing on cancer diseases that have a significant impact on people’s healthy lifespan, and we expect that we will be able to expand our business and establish ourselves as a digital healthcare platform that can manage an individual’s disease status in the future.” He expressed his aspirations.
On the other hand, KIMES is an exhibition specializing in medical devices and hospital facilities that has grown steadily with the development of the Korean medical industry since its first meeting in 1980. It has transformed into a technology-intensive high-tech industry such as rehabilitation medicine.
KIMES 2023 will feature new technologies and new products suitable for the era of convergence, such as smart healthcare in the era of the 4th Industrial Revolution, robotic medicine and eco-friendly medical waste facilities, cutting-edge hospital facilities, medical information systems combined with IT technology, and the automobile industry for rapid patient transportation. presents. In addition, it provides a variety of information, including seminars on medical technology, new technology, and overseas marketing, as well as domestic medical industry policy seminars that will show the latest information and direction of the medical industry.